MX2022010955A - Metodos para tratar el cancer usando (r)-n-(3-fluoro-4-((3- ((1-hidroxipropan-2-il)amino)-1h-pirazolo[3,4-b]piridin-4-il)oxi) fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetrahidro pirimidin-5-carboxamida. - Google Patents

Metodos para tratar el cancer usando (r)-n-(3-fluoro-4-((3- ((1-hidroxipropan-2-il)amino)-1h-pirazolo[3,4-b]piridin-4-il)oxi) fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetrahidro pirimidin-5-carboxamida.

Info

Publication number
MX2022010955A
MX2022010955A MX2022010955A MX2022010955A MX2022010955A MX 2022010955 A MX2022010955 A MX 2022010955A MX 2022010955 A MX2022010955 A MX 2022010955A MX 2022010955 A MX2022010955 A MX 2022010955A MX 2022010955 A MX2022010955 A MX 2022010955A
Authority
MX
Mexico
Prior art keywords
hydroxypr
opan
tetrahydropyrimidin
pyrazolo
dioxo
Prior art date
Application number
MX2022010955A
Other languages
English (en)
Spanish (es)
Inventor
Karyn Sue Bouhana
Jim Yuk- Fai Wong
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2022010955A publication Critical patent/MX2022010955A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2022010955A 2020-03-03 2021-03-01 Metodos para tratar el cancer usando (r)-n-(3-fluoro-4-((3- ((1-hidroxipropan-2-il)amino)-1h-pirazolo[3,4-b]piridin-4-il)oxi) fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetrahidro pirimidin-5-carboxamida. MX2022010955A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062984458P 2020-03-03 2020-03-03
US202163133501P 2021-01-04 2021-01-04
PCT/IB2021/051693 WO2021176330A1 (en) 2020-03-03 2021-03-01 Methods to treat cancer using (r)-n-(3-fluoro-4-((3-((1-hydroxypropan-2-yl)amino)-1h-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide

Publications (1)

Publication Number Publication Date
MX2022010955A true MX2022010955A (es) 2022-10-07

Family

ID=74860342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010955A MX2022010955A (es) 2020-03-03 2021-03-01 Metodos para tratar el cancer usando (r)-n-(3-fluoro-4-((3- ((1-hidroxipropan-2-il)amino)-1h-pirazolo[3,4-b]piridin-4-il)oxi) fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetrahidro pirimidin-5-carboxamida.

Country Status (12)

Country Link
US (1) US20230117328A1 (enExample)
EP (1) EP4114397A1 (enExample)
JP (2) JP7181325B2 (enExample)
KR (1) KR20220148867A (enExample)
CN (1) CN115529816A (enExample)
AU (1) AU2021231435A1 (enExample)
BR (1) BR112022017267A2 (enExample)
CA (1) CA3174064A1 (enExample)
IL (1) IL296060A (enExample)
MX (1) MX2022010955A (enExample)
TW (2) TWI775333B (enExample)
WO (1) WO2021176330A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023002360A1 (en) * 2021-07-22 2023-01-26 Pfizer Inc. Solid forms and formulations of an inhibitor of tam and c-met kinases
CN122140719B (zh) * 2026-04-15 2026-07-28 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） Sgi-7079在治疗flt3突变型急性髓系白血病中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US10195208B2 (en) * 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2016019270A1 (en) 2014-07-31 2016-02-04 Academia Sinica An antagonistic pd-1 aptamer and its applications in cancer therapy related applications
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met

Also Published As

Publication number Publication date
CN115529816A (zh) 2022-12-27
TW202317125A (zh) 2023-05-01
JP2023009250A (ja) 2023-01-19
TWI814504B (zh) 2023-09-01
BR112022017267A2 (pt) 2022-12-13
WO2021176330A1 (en) 2021-09-10
IL296060A (en) 2022-10-01
AU2021231435A1 (en) 2022-09-22
JP2021138693A (ja) 2021-09-16
EP4114397A1 (en) 2023-01-11
JP7181325B2 (ja) 2022-11-30
TWI775333B (zh) 2022-08-21
US20230117328A1 (en) 2023-04-20
TW202146025A (zh) 2021-12-16
CA3174064A1 (en) 2021-09-10
KR20220148867A (ko) 2022-11-07

Similar Documents

Publication Publication Date Title
PH12022551169A1 (en) METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
MY200810A (en) Pyrrolidine compounds
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2023001468A (es) Tratamiento de cancer de prostata.
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
MX2010002396A (es) Metodos para administrar n-(5-ter-butil-isoxazol-3-il)-n?-{4-[7-(2 -morfolin-4-il-etoxi)imidazo[2, 1-b][1,3]benzotiazol-2-il] fenil} urea para tratar enfermedaes proliferativas.
MX2023009520A (es) Compuesto de 4-aminoquinazolina.
CY1111786T1 (el) Βιταμινη κ για την προληψη και τη θεραπευτικη αντιμετωπιση του δερματικου εξανθηματος μετα απο anti-egfr θεραπεια
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
MX2020010034A (es) Metodo de tratamiento de enfermedad fibrotica.
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2024011705A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion y aplicacion farmaceutica
BR112022017267A2 (pt) Métodos para tratar o câncer usando (r)-n-(3-fluoro-4-((3-((1-hidroxipropan-2-il) amino)-1h-pirazolo[3,4-b]piridin-4-il)óxi)fenil)-3-(4-fluorofenil)-1-isopropil-2,4-dioxo-1,2,3,4-tetra-hidropirimidina-5-carboxamida
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
EP4461362A3 (en) Nk1-antagonist combination and method for treating synucleinopathies
MX2019010651A (es) Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.
PH12021553098A1 (en) Treatment for synucleinopathies
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.